Abstract: A lactic acid bacterium-containing composition including a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof, wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 ?g to 1.0 ?g per 1×108 lactic acid bacteria; a therapeutic oral pharmaceutical composition for at least one of an HPV infectious disease and an HPV-associated tumor which includes the lactic acid bacterium-containing composition; and a mucosal immunity-inducing agent which includes the lactic acid bacterium-containing composition.

Abstract: Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were cultured to prepare a mesenchymal stem cell sheet. Four weeks after induction of myocardial infarction in rats, the mesenchymal stem cell sheet was transplanted to the heart. The mesenchymal stem cell sheet were readily engrafted to the surface of the scarred myocardium, grew gradually in situ, and formed a thick layer (approximately 600 ?m) in 4 weeks. The grown transplanted mesenchymal tissue contained newly formed blood vessels, myocardial cells, and undifferentiated mesenchymal cells.

Abstract: The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.

Abstract: In order to provide (i) a medical composition that has a strong angiogenic effect, has low invasiveness to a body of a patient, and is easy to administer to a living subject and (ii) a medical kit using a medical composition, the medical composition includes: a carrier in a particle form, the carrier having (a) a support made from a bioabsorbable polymer and (b) a surface layer made from hydroxyapatite and provided on the support; and cells provided on a surface of the carrier.

Abstract: Disclosed are: a gene transduction method for use in the induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes effectively; stem cells into each of which a gene useful for the induction of the differentiation into hepatocytes is introduced; and hepatocytes produced from stem cells each having the gene introduced therein. A specific gene can be introduced into stem cells such as ES cells or iPS cells using an adenovirus vector. The effective induction of the differentiation into hepatocytes can be achieved by introducing the gene. Specifically, the effective induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes can be achieved by introducing at least one gene selected from HEX gene, HNF4A gene, HNF6 gene and SOX17 gene into the stem cells.

Abstract: The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.

Abstract: Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein comprising an L2-epitope of a human papillomavirus (HPV) type-16 inserted in a loop region of a human papillomavirus type-16 L1 protein; and a capsid which is a particle formed by the chimeric protein. The loop region to which the L2-epitope is to be inserted is located between an amino acid residue at position-430 and an amino acid residue at position-433. The L2-epitope has an amino acid sequence represented by any one of the following formulae: LYKTCKQAGTCPPDIIPKVEG (SEQ ID NO: 2) (18-38 L2-epitope); GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (56-75 L2-epitope); and DPVGPLDPSIVSLVEESSFI (SEQ ID NO: 4) (96-115 L2-epitope).

Abstract: Provided is a novel and creative dental tissue regeneration method for regenerating dental tissue after pulpectomy or the enlargement and cleaning of an infected root canal. After pulpectomy or the enlargement and cleaning of an infected root canal, a root canal filler (200) having an extracellular matrix (210) containing the cells (220) enriched for dental pulp stem cells, is inserted into the apical side of the root canal of a target tooth (100). The cells including dental pulp stem cells include at least one of the following: dental pulp SP cells, CD31-negative and CD146-negative cells, CD24-positive cells, CD105-positive cells, and CD150-positive cells. For instance, dental pulp SP cells are CD31? and CD146? negative. Even if pulpitis due to deep caries occurs, appropriate dental pulp regeneration and recovery of dental pulp function are possible.

Abstract: The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.

Abstract: An electrostimulator includes a boost circuit supplying a stimulus signal, first and second electrodes disposed on a skin surface, detecting a voluntary myoelectric signal and giving the stimulus signal, an amplification circuit amplifying the voluntary myoelectric signal, a controller controlling the stimulus signal in accordance with the voluntary myoelectric signal, an H-bridge circuit including first and third switches connected in series and connected to the second electrode, and second and fourth switches connected in series and connected to the first electrode, the first to the fourth switches being connected in parallel, an isolated DC-DC converter supplying a power to the controller and the amplification circuit, a regulator outputting a midpoint voltage of a power-supply voltage, and a third electrode connected to the regulator and a reference terminal of the amplification circuit and disposed on the skin surface.

Abstract: Disclosed is a method for production of a bio-derived scaffold for use in regenerative medicine, which has a bio-compatibility and biodegradability and can self-organize and grow without causing calcification. The method comprises the steps of partially fixing a biological soft tissue with glutaraldehyde by cross-linking and incubating the partially fixed tissue together with an elastase.

Abstract: A method of detecting a poor-prognosis stage I lung adenocarcinoma in a mammal, comprising a step of measuring the copy number of ACTN4 gene in the cells of the stage I lung adenocarcinoma tissue obtained from the mammal, wherein, when the copy number of the gene exceeds 4, the stage I lung adenocarcinoma in the mammal is predicted to be a poor-prognosis stage I lung adenocarcinoma.

Abstract: A cardiac disease treating system has an input part for inputting a patient's indexes of kinetics of blood circulation including at least heart rate, a cardiac oxygen consumption calculation monitor unit for calculating the estimated value of said patient's amount of cardiac oxygen consumption based on the indexes of kinetics of blood circulation input from the input part, and a cardiac oxygen consumption curtailment unit for comparing the heart rate input from the input part and the critical heart rate minimizing the estimated value of amount of cardiac oxygen consumption calculated by the cardiac oxygen consumption monitor unit and controlling the patient's heart rate in conformity with the results of this comparison.

Abstract: A dental CAD/CAM device capable of accurately forming a dental coating is provided. The device includes: an intraoral-site measurement section 100 configured to measure 3D shape data on an intraoral site 130 with an OCT probe 150 for obtaining a tomogram of an object using near-ultraviolet light; a treatment-target-tooth 3D shape data acquisition section 200 configured to acquire shape data of a treatment target tooth from 3D shape data obtained by the intraoral-site measurement section 100; and a coating object 3D shape data creation section 300 configured to create 3D shape data on a dental coating such that the dental coating matches the 3D shape data of the treatment target tooth obtained by the treatment target tooth 3D shape data acquisition section 200.

Abstract: Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a compound capable of increasing the quantity of N-acetylneuraminic acid in cells. Examples of the compound to be contained in the therapeutic pharmaceutical agent include N-acetylneuraminic acid, an intermediate produced downstream from N-acetylmannosamine in an N-acetylneuraminic acid biosynthesis pathway, an N-acetylneuraminic acid derivative, an N-acetylmannosamine derivative, an N-acetylneuraminic acid-containing compound, an N-acetylneuraminic acid derivative-containing compound, an N-acetylmannosamine-containing compound, an N-acetylmannosamine derivative-containing compound, an inhibitor of a degrading enzyme for N-acetylneuraminic acid, an inhibitor of a degrading enzyme for N-acetylmannosamine, an inhibitor of a degrading enzyme for the intermediate, and others.

Abstract: Problems To provide a cardiac disease treatment system for accurately diagnosing the functional cause of an abnormality of a cardiac disease by analyzing the hemodynamic state of a patient, automatically performing medication in accordance with the diagnosis result, and treating the cardiac disease. Means for solving problems The cardiac disease treatment system is characterized by comprising input means (2) for inputting the cardiac output value of the patient, the left atrial pressure value and/or the right atrial pressure value, first calculating means (31) for calculating the pumping ability value of the left heart or the right heart from the inputted cardiac output and the left or right atrial pressure value, first comparing means (41) for comparing the pumping ability value of the left heart or the right heart with a target pumping ability value, and first medicating means (51) for medicating the patient in accordance with the result of the comparison by the first comparing means (41).

Abstract: Provided are a micro RNA which can be used as a colon cancer marker, a method for testing for colon cancer which uses the micro RNA which can be used as a colon cancer marker, and a test kit which can be used for the testing method. The colon cancer marker includes micro RNA molecules which are represented by any of the sequences 1 through 25. The method for testing for colon cancer in a subject involves preparing a sample, which contains a micro RNA molecule derived from the subject's colon tissue or colon cell, and detecting a micro RNA molecule represented by any of the sequences 1 through 25 present in the obtained sample.

Abstract: Disclosed are: a gene transduction method for use in the induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes effectively; stem cells into each of which a gene useful for the induction of the differentiation into hepatocytes is introduced; and hepatocytes produced from stem cells each having the gene introduced therein. A specific gene can be introduced into stem cells such as ES cells or iPS cells using an adenovirus vector. The effective induction of the differentiation into hepatocytes can be achieved by introducing the gene. Specifically, the effective induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes can be achieved by introducing at least one gene selected from HEX gene, HNF4A gene, HNF6 gene and SOX17 gene into the stem cells.

Abstract: The invention provides compositions comprising a TERT-RMRP or TERT-RNA complex and methods of treating subjects with genetic diseases in which gene silencing is either increased by administering the compositions of the invention or decreased by administering an inhibitor of the RNA-dependent RNA polymerase (RdRP) activity of these compositions. Moreover, the invention provides methods of screening for agonists and antagonists of RdRP activity and TERT-RMRP complex formation. Finally, the invention provides a method of identifying a RNA molecule that forms a complex with a TERT polypeptide and has RdRP activity.

Abstract: A novel protein and a fragment thereof useful as a tumor marker of pancreatic cancer are disclosed. This protein or a fragment thereof is a modified ?-fibrinogen protein containing an oxidized amino acid residue(s) or a fragment thereof containing said oxidized amino acid residue(s). The oxidized amino acid residue(s) is one or more amino acid residues selected from the group consisting of (a) a proline residue corresponding to the proline residue at the position of 530 in SEQ ID NO: 2, and (b) a proline residue corresponding to the proline residue at the position of 565 in SEQ ID NO: 2.